These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Ionic titanocene complexes: a new type of antitumor agent. Köpf-Maier P, Neuse E, Klapötke T, Köpf H. Cancer Chemother Pharmacol; 1989; 24(1):23-7. PubMed ID: 2720888 [Abstract] [Full Text] [Related]
13. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour. Valadares MC, Ramos AL, Rehmann FJ, Sweeney NJ, Strohfeldt K, Tacke M, Queiroz ML. Eur J Pharmacol; 2006 Mar 18; 534(1-3):264-70. PubMed ID: 16513106 [Abstract] [Full Text] [Related]
14. Preclinical evaluation of dichlorobis(1-phenylbutane-1,3-dionato)titanium (IV) and budotitane. Two representatives of the new class of antitumor-active bis-beta-diketonato metal complexes. Keppler BK, Schmähl D. Arzneimittelforschung; 1986 Dec 18; 36(12):1822-8. PubMed ID: 3566844 [Abstract] [Full Text] [Related]
16. [Histomorphologic changes in Jensen sarcoma following radiotherapy, titanocene dichloride treatment and combination therapy]. Uhl J, Langrock K, Krieghoff B, Hambsch K. Radiobiol Radiother (Berl); 1987 Dec 18; 28(1):51-7. PubMed ID: 3588859 [No Abstract] [Full Text] [Related]
17. Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas. Köpf-Maier P. J Cancer Res Clin Oncol; 1987 Dec 18; 113(4):342-8. PubMed ID: 3036884 [Abstract] [Full Text] [Related]